These authors contributed equally to this work.
Introduction
Glycosaminoglycans (GAGs) play key roles in diverse biological processes. Yet, only a handful of GAGs have reached the clinic including unfractionated heparin, low molecular weight heparins and fondaparinux. A priori, oligomeric GAGs (e.g., degree of polymerization (dp) 4 to dp10) can be expected to function better as therapeutic agents than polymeric GAGs because of the possibility of reduced non-specific interactions and heterogeneity. In fact, several GAG oligosaccharides have been discovered to date as targeting proteins with higher level of specificity (Maimone and Tollefsen 1990; Copeland et al. 2008; Raghuraman et al. 2010; Patel et al. 2016; Sankaranarayanan et al. 2017 ). Yet, it has been difficult to develop GAG oligosaccharides as drugs. One of the key reasons for this state of art is that GAG synthesis is extremely challenging. Synthesizing GAG oligosaccharides takes years of effort and is highly structure-specific (Arungundram et al. 2009; Liu and Linhardt 2014; Sankaranarayanan et al. 2017; Zong et al. 2017 ).
An alternative approach is to access GAG oligosaccharides using enzymatic depolymerization of polymeric GAGs. Several enzymes are available including heparinases I, II and III, which cleave heparin/heparan sulfate (H/HS), and chondroitinases A, B and C, which cleave chondroitin and dermatan sulfates. These enzymes represent powerful tools to theoretically generate multiple oligosaccharides in parallel. In fact, several groups have reported preparation of sequences longer than di-and tetra-saccharides, especially using heparinase I (Pervin et al. 1995; Hileman et al. 1997; Chuang et al. 2002; Fu et al. 2014; Brown and Kuberan 2015; Powell et al. 2010; Wei et al. 2011) . This is despite the observation that di-and tetrasaccharides are the dominant products in digestion of H/HS (Silva and Dietrich 1975; Carnachan et al. 2016) . A key strategy that is used in the generation of longer oligosaccharides is partial digestion, which insufficiently depolymerizes heparin resulting in small amounts of longer chains. This strategy is useful but challenging. In addition, it is difficult to implement with high consistency, which implies that every batch of depolymerization requires individualized processing.
We reasoned that enzyme immobilization may open a route to longer oligosaccharides. Heparinase immobilization was developed long ago (Bhushan et al. 2017) to effect de-heparinization of human blood (Langer et al. 1982; Linhardt et al. 1984) . Systematic investigations of parameters related to immobilization homogeneity, catalytic activity, enzyme stability, types of supports and chemistries were performed (Bernstein et al. 1987a (Bernstein et al. , 1987b Leckband and Langer 1991) , which led to the conclusion that CNBr-activated agarose was the most optimal support to ensure isotropicity, high efficiency and stability. In this work we show that heparinase I immobilization is intrinsically capable of producing longer oligosaccharides even under a batch process. The product composition shifts more in the direction of longer oligosaccharides under flow conditions. Interestingly, immobilization changes the pH and temperature optimum. Overall, this technology is likely to offer a simple and cost effective route to preparation of larger amounts of longer H/HS sequences.
Results and discussion
Following literature reports, heparinase I was immobilized on to CNBr-activated Sepharose-4B over a period of 18 h at 4°C. The beads displayed heparin degrading activity, while the supernatant or subsequent washings displayed no activity (not shown) suggesting retention of~100% of activity. The eliminase activity of immobilized heparinase I at pH 7.0 and 30°C increased with time, as expected, with a gradual saturation in the production of unsaturated uronic acid species by about 24 h ( Figure 1A ). This implied that under batch process, 24 h incubation tended to be sufficient for reaching an equilibrium. To monitor kinetics of elimination, we measured the initial rate of A 232 increase as a function of heparin concentration ( Figure 1B ), which demonstrated traditional Michaelis kinetics with a K M of 26.5 mg/mL at pH 7.0 and 30°C. In comparison, an earlier work has noted a K M of 60 mg/mL (Linhardt et al. 1984) , while another lists a value of 0.15 mg/mL (Yang et al. 1988 ). The differences most probably arise from the differences in immobilization matrix and conditions.
The immobilized enzyme was then characterized for its pH, temperature, and reusability optima. In our experiments, free heparinase I was found to exhibit stability in the range of pH 6.5 to 8.0 with an optimum of pH 8.0 ( Figure 1C ). In contrast, immobilized heparinase I was found to exhibit moderate to excellent activity in range of pH 5.0 to 8.0 with an optimal pH of 5.5. We also monitored eliminase activity of immobilized and free enzymes at 5, 15, 25, 30, 37, 42 and 50°C. Whereas the free enzyme displayed an optimum at 30°C ( Figure 1D ), immobilized heparinase I displayed reasonable activity at all temperatures, except for 5°C ( Figure 1D ) suggesting a significant improvement in thermal stability. Interestingly, the temperature optimum was found to be 15°C. Although the likely reasons for the shift in temperature optimum are not clear, immobilization has been known to affect the dynamics and stability of enzymes (Zucca et al. 2016) .
To assess whether immobilization alters the composition of products formed following heparin degradation, we utilized reversed phase-ion pairing (RP-IP) ultrahigh pressure liquid chromatography The eliminase activity of immobilized heparinase I was also followed under different pH (C) and temperature (D) conditions. Shown are A 232 values at 24 h for samples of heparin (10 mg/mL) incubated with immobilized enzyme. Immobilized enzyme data in C and D panels is shown in lighter (or green & orange) colour, whereas free enzyme data is shown in darker (or blue) colour. Errors being reported are standard deviations (n = 3-4). This figure is available in black and white in print and in colour at Glycobiology online.
(UPLC) coupled to ESI-MS analysis. Our method utilized a shallow gradient of organic solvent in water with hexylamine as an IP agent and hexafluoro-2-propanol as an organic modifier at 40°C for resolution of oligosaccharides. Figure 2 shows RP-IP UPLC-ESI-MS profile of heparin samples digested with immobilized heparinase I. Digestion was performed for 24 h in a batch process at temperature and pH in the range of 5 to 50°C and 5.0 to 8.0, respectively. For studying the influence of temperature, the pH was held constant at 7.0, whereas the temperature was 30°C for studying the pH effect. Heparin degradation produced different profiles depending on both temperature and pH; however, the profiles at pH 5.5, 30°C and pH 7.0, 15°C showed distinct enhancement in peak intensities corresponding to oligosaccharides with chain lengths of 4, 6 and 8 (Figure 2A and B) . A closer look at the two figures reveals some degradation at 30 and 37°C, but not much at 25 and 50°C; however, the A 232 profiles indicate gradual decrease in level of degradation as the temperature reaches 50°C ( Figure 1D ). We infer that the variation in peak intensities observed in the LC-MS experiments arise from differing ionizabilities of oligosaccharides.
Interestingly, combination of optimal conditions, i.e., pH 5.5 and 15°C, did not show a dramatic increase in the proportions of longer sequences. ESI-MS analysis showed that the major oligosaccharides formed at pH 5.5 and 15°C were dp4 5,0 , dp4 6,0 , dp6 9,0 , dp8 12,0 and dp10 14,2 (nomenclature refers to dp followed by the number of sulfate and acetate groups, respectively) ( Figure 2C ). Based on A 232 values these represent nearly 60-80% of the total. The proportion of disaccharides formed under this condition was less than 25%.
In contrast, free heparinase I did not produce significant proportions of chains longer than dp2 ( Figure 2C and Supplementary Fig S1) . In fact under conditions that appear to be optimal for free heparinase to function (i.e., pH 7.0 and 30°C), heparin disaccharides were the dominant products (>60%), which is consistent with literature reports. Thus, conditions employed in immobilized heparinase I depolymerization of heparin intrinsically bias the product distribution to longer oligosaccharides. This is of substantial importance because kinetic control of depolymerization reaction is fraught with many difficulties. Additionally, oligosaccharides typically produced through kinetic control of depolymerization possess repeating units of heparin, i.e., dp2 3,0 or ΔUA2S-GlcNS6S, whereas immobilized heparinase I produced acetylated oligosaccharides, e.g., dp10 13,2 , dp10 14,2 and dp10 17,2 (~-25-30%). This implies that strong possibilities exist for generation of sequences with variant substitution pattern in comparison to free heparinase I based degradation of heparin.
To assess whether the advantages gained with immobilization of heparinase I could be expanded further, we utilized flow conditions, rather than batch processing. Heparin in acetate buffer, pH 5.5, at 15°C was circulated for 24 h over the enzyme matrix (Figure 3 , see also Supplementary Fig. S1 ). Comparison of batch vs. flow product profiles shows that the proportion of dp2 sequences reduces even further under flow conditions (22% vs. 10%, Supplementary Fig. S1 ). Likewise, the proportion of dp10 or longer sequences also reduce in the flow process from that in the batch process (35% vs. 12%). In combination, this results in more of dp4, dp6 and dp8 sequences in the flow process. In contrast, free heparinase I in a batch process produces much smaller proportions of dp6, dp8 and dp10 oligosaccharides (Figure 3) . It is important to note that the flow conditions employed in these studies are not truly flow chemistry-like conditions because of the repeated cycling of substrate solution. Although the nature of control remains to more rigorously established, we expect that optimal exploitation of true flow technology may result in further fine control of heparin depolymerization.
A major putative advantage of immobilization of enzymes vs. their free form is the possibility of repeated use. Higher temperature and pH stability of heparinase I in the immobilized state, noted above, could imply higher re-cycling capacity. Thus, we measured eliminase activity of immobilized heparinase I in a batch process over multiple cycles. Following a 24 h (or 12 h) cycle, immobilized heparinase I was washed repeatedly with buffer at room temperature and the reaction re-started using the starting concentration of heparin (13 mg/mL). As shown in Supplementary Figure S2 , immobilized heparinase I retained good activity at least up to five cycles and in some instances could be re-used well until the eighth cycle (not shown). Similarly observations were made earlier with heparinase I (Bernstein et al. 1987a; Wu et al. 2014) . . The pH was 7.0 for studying temperature effect, where the temperature was 30°C for studying pH effect. Heparin (10 mg/mL) was incubated for 24 h with immobilized enzyme (50 mg containing 0.05 IU of heparinase I) followed by collection of sample for UPLC-MS analysis. (C) The proportion of different oligosaccharides formed at 24 h following heparin digestion by either free or immobilized heparinase I in acetate buffer, pH 5.5, at 15°C. RP-IP UPLC-ESI-MS was used to resolve and identify oligosaccharides. Heparin (15 mg/mL) was incubated with free (0.05 IU) or immobilized enzyme (50 mg containing 0.05 IU). Experiments were performed at least in duplicate and errors being reported are standard deviations. This figure is available in black and white in print and in colour at Glycobiology online.
Significance
The key result of this work is that immobilization of heparinase I tends to produce longer oligosaccharides from heparin in comparison to that in the free form. Initial evidence was also obtained for depolymerization under flow, which enhances the proportion of longer oligosaccharides further. Additional results that evince interest are that immobilization enables heparinase I to exhibit activity over a wider range of pH (5-8), temperature (5-50°C) and reusability (at least five cycles).
The primary implication of these results is heparinase I immobilization may offer a simple and cost effective route to preparation of larger amounts of longer sequences. This does not imply that these longer sequences are simply not obtained in free heparinase I degradation of heparin, because they are as discussed in the introduction section, but immobilization enhances their proportion. This is of considerable importance. The pace of discovery of longer sequences as therapeutically relevant is increasing these days (Copeland et al. 2008; Patel et al. 2016; Sankaranarayanan et al. 2017 ), yet their synthesis or preparation is not an easy task. A much finer aspect of the immobilized heparinase I technology is that the longer sequences produced are not all oligomers of the most common heparin disaccharide dp2 3,0 (ΔUA2S-GlcNS6S). In fact, acetylated oligosaccharides, e.g., dp10 13,2 , dp10 14,2 and dp10 17,2 , were identified in the depolymerization reaction suggesting a strong possibility of deriving a reasonably diverse library.
The eventual implementation of this type of immobilized heparinase technology for preparation of homogeneous oligosaccharides will have to involve additional steps. As demonstrated in the literature, strong anion exchange and size exclusion chromatographies coupled with membrane or tangential flow filtration technologies would be important for resolving the oligosaccharide mixture. The engineering advances being made with regard to these technologies can be particularly helpful in this process. Thus overall, this work contributes key tools that would enable better understanding of GAG biology.
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Supplementary data is available at Glycobiology online.
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